ConnectiveRx

Overview

ConnectiveRx is the largest independent outsourced commercialization platform for pharma manufacturers, spanning hub services, copay assistance, and EHR-based awareness and adherence (A&A) across 140+ manufacturers and 550+ brands. Genstar Capital is the majority owner. As of September 2025, ConnectiveRx operates a fully licensed dispensing pharmacy for end-to-end direct-to-patient distribution, making it one of the few independent hubs with owned dispensing alongside its core hub, copay, and EHR network capabilities.

ConnectiveRx is not a wholesaler-owned hub, a pure copay-card processor, or a specialty pharmacy. The platform’s distinctive shape is the combination: top-3 copay administration integrated at pharmacy point of sale, the 1.2M+ prescriber EHR-integrated A&A network, traditional hub case management, and owned dispensing under one operator.

Hub Capability Model

The framework below standardizes how Rx Almanac evaluates hub-services capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, ConnectiveRx is evaluated as an independent commercialization platform combining hub, copay, EHR awareness and adherence, and owned dispensing.

Capability	Buyer should compare	ConnectiveRx readout
Therapy initiation and enrollment intake	Digital and human intake, eConsent, missing-information resolution, provider/patient portals, and clean case creation.	Core intake workflow. Hub portal supports web-based patient enrollment and benefit-verification data entry; EHR-integrated messaging reaches 1.2M+ prescribers for upstream intake.
Benefits verification and coverage triage	Medical/pharmacy benefit verification, eligibility checks, payer-policy lookup, coverage routing, and speed from referral to actionable case.	Core coverage workflow. BV and PA for self-administered specialty drugs run through the hub case-management stack; confirm payer-mix depth and automation rate in RFP.
Prior authorization, appeals, and reimbursement casework	PA initiation, payer-specific forms, clinical documentation, appeals, denial management, and field reimbursement handoffs.	Core PA casework. Tech-enabled call center plus web portal manage the reimbursement process for specialty drugs; ask for denial-rate analytics and field reimbursement manager handoff.
Affordability, PAP, and copay operations	Copay, free-drug, bridge, foundation, income verification, PAP renewal, and gross-to-net sensitive affordability logic.	Core affordability operations. Top-3 copay card processor integrated at pharmacy point of sale; PAP, free-drug, foundation, and bridge programs run through the same operating model.
Patient engagement and adherence operations	Omnichannel reminders, clinical education, nursing or training escalation, persistence outreach, and patient-facing support quality.	Core engagement model. EHR-integrated messaging to prescribers, pharmacists, and patients is the proprietary differentiator; A&A network reaches 1.2M+ prescribers.
Fulfillment, specialty pharmacy, and distribution coordination	Routing to SPs, non-commercial dispensing, DTP shipment, sample/replacement product, 3PL, and cold-chain handoffs.	Core fulfillment handoff. Fully licensed dispensing pharmacy launched September 2025 enables end-to-end DTP distribution; Careform non-commercial pharmacy operates alongside SP routing.
Program reporting, integrations, and governance	Manufacturer dashboards, KPI reporting, CRM/EHR/API integrations, SLA governance, and operating visibility across vendors.	Reporting layer. Manufacturer dashboards across hub, copay, and A&A workstreams; confirm unified reporting across the dispensing-pharmacy and EHR-A&A network for the proposed program.

Buyer Fit

• Procurement trigger: Evaluate ConnectiveRx when a launch needs hub, copay, and EHR-A&A operations under one independent operator, particularly where EHR-integrated prescriber messaging is the wedge against vendors that lack a proprietary network.
• Best-fit buyers: Pharma manufacturers and biotech launch teams in immunology/autoimmune, endocrinology/diabetes, neurology, cardiology, and oncology programs; specialty, biologics, small molecule, and biosimilar drug types.
• Less ideal fit: Programs that need a wholesaler-bundled hub tied to drug distribution, a pure DTP digital-pharmacy operator, or a specialty pharmacy as the primary contracting party.
• Commercial fit: Custom/RFP pricing; reported 98% customer retention indicates high switching costs once integrated, so scope and SLA design at award matter more than typical.
• Scope diligence: Staffing model (dedicated vs. pooled across the 550+ brand book), launch-surge plan, data feeds into incumbent CRM and data-lake environments, dispensing-pharmacy capacity and LDD-network access, and division of labor with partner specialty pharmacies.

Differentiators

• Independent operator at scale: 140+ manufacturers, 550+ brands, and the only independent provider with top-tier Hub, Copay, and Awareness & Adherence capabilities under one platform.
• 1.2M+ prescriber EHR-integrated A&A network: EHR-integrated messaging to prescribers, pharmacists, and patients is the proprietary asset and a structural differentiator vs. hubs that buy A&A as a third-party service.
• Top-3 copay administration integrated at pharmacy point of sale: High-volume copay processing tied directly to the pharmacy claim transaction; differentiator vs. copay vendors that operate downstream of the claim.
• Owned dispensing pharmacy (September 2025): Fully licensed dispensing pharmacy enables end-to-end DTP distribution; one of the few independent hubs with this capability.
• ShieldRx (April 2026): Product launched with EagleForce in direct response to IRA-driven shifts in payer cost-sharing dynamics.
• 20% CAGR and 98% customer retention: Fastest-growing platform segment is driven by specialty drug volume and share gains; high retention indicates depth of integration once a manufacturer is live.

RFP Questions

• Which steps are performed by ConnectiveRx, by a partner specialty pharmacy, and by the manufacturer?
• What median time-to-therapy, PA turnaround, and first-fill conversion metrics can be reported by brand?
• How are benefit verification, PAP, copay, and adherence data reconciled into manufacturer dashboards across the hub, copay, and A&A workstreams?
• What EHR coverage and prescriber-targeting capabilities does the 1.2M+ network deliver for the therapy area in scope?
• How does the owned dispensing pharmacy interact with partner specialty pharmacies for LDD-network products?
• What ShieldRx capabilities apply to the proposed program, and how do they address IRA-driven cost-sharing dynamics?
• What launch-surge staffing, training, and bilingual coverage commitments are available in the first 90 days?

Recent Activity

• 2026-04 - Launched ShieldRx with EagleForce as a direct response to IRA-driven shifts in payer cost-sharing dynamics.
• 2025-12 - Conference leadership presence at industry events covering hub, copay, and A&A topics.
• 2025-09 - Expanded pharmacy services with fully licensed dispensing capability for end-to-end DTP distribution.
• 2024 - Snehal Desai appointed CTO.
• 2024-07 - RxLink partnership to expand patient medication affordability options.